Seeking Alpha

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access ...
Insider Monkey

ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On June 2, ImmunityBio Inc. (NASDAQ:IBRX) announced that it attained Expanded Access ...
MarketWatch

UK MHRA Approves ImmunityBio's ANKTIVA(R) Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

The MarketWatch News Department was not involved in the creation of this content. -- ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate ...
Hosted on MSN

ImmunityBio gets FDA expanded access authorization to treat lymphopenia with Anktiva

ImmunityBio (NASDAQ:IBRX) said on Monday that the U.S. FDA has approved expanded access for its Cancer BioShield platform, featuring Anktiva, to treat lymphopenia in adults suffering from advanced or ...
Nasdaq

ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

CULVER CITY, Calif. & RIYADH, Saudi Arabia--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the signing of a strategic Memorandum of Understanding ...
Nasdaq

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Oral presentation provides update from QUILT-3.032 on durable complete responses to ANKTIVA® plus BCG in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) with or ...
Insider Monkey

ImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield™ Platform

We recently published 10 Best Biotech Stocks to Buy Under $10. ImmunityBio, Inc. is among them. ImmunityBio, Inc. (NASDAQ:IBRX) is a commercial-stage biotechnology company developing next-generation ...